Journal of Experimental Pathology
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Dr. Bhalchandra Mirlekar is an immunologist with a deep and long-lasting interest in how the immune response shapes cancer and autoimmune disease. He is leveraging the immunosuppressive populations that restrain anti-tumor immunity in pancreatic cancer and malignant melanoma, with developing new immune-based therapy options for these deadly malignancies. He acquired the knowledge, training and experience in the field of immunology to effectively carry out research in basic immunology for better translation of research findings to clinical applications. He worked on molecular mechanism of T cell differentiation associated with auto-inflammatory responses. He proposed that the regulatory T cell (Treg) function and cytokine signaling dictates the balance between Treg and Th17 cells. In addition to many first-author publications, He have written several collaborative co-authored peer-reviewed publications in collaboration during my research studies. Currently, He is also working on cellular and molecular mechanisms of B cell-mediated immune responses during pancreatic cancer and malignant melanoma initiation and progression
Tumor immunology, Cancer immunotherapy: Drug discovery, clinical trials, studies on cancer patient samples , Molecular mechanism behind generation of innate and adaptive immune responses, Immune cell and cytokine signaling, Generation of transgenic, gene knock-out, cancer and autoimmune animal models, Flow cytometry based research
Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.